DE69839812D1 - Analoge des menschlichen interferon-alpha mit niedriger toxizität - Google Patents

Analoge des menschlichen interferon-alpha mit niedriger toxizität

Info

Publication number
DE69839812D1
DE69839812D1 DE69839812T DE69839812T DE69839812D1 DE 69839812 D1 DE69839812 D1 DE 69839812D1 DE 69839812 T DE69839812 T DE 69839812T DE 69839812 T DE69839812 T DE 69839812T DE 69839812 D1 DE69839812 D1 DE 69839812D1
Authority
DE
Germany
Prior art keywords
low toxicity
analogue
human interferon
interferon alpha
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839812T
Other languages
English (en)
Inventor
Howard M Johnson
Carol H Pontzer
Lorelie H Villarete
Jackeline Campos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Pepgen Corp
Original Assignee
University of Florida
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, Pepgen Corp filed Critical University of Florida
Application granted granted Critical
Publication of DE69839812D1 publication Critical patent/DE69839812D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69839812T 1997-10-20 1998-10-20 Analoge des menschlichen interferon-alpha mit niedriger toxizität Expired - Lifetime DE69839812D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs
PCT/US1998/021936 WO1999020653A1 (en) 1997-10-20 1998-10-20 Low-toxicity human interferon-alpha analog

Publications (1)

Publication Number Publication Date
DE69839812D1 true DE69839812D1 (de) 2008-09-11

Family

ID=25495373

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839812T Expired - Lifetime DE69839812D1 (de) 1997-10-20 1998-10-20 Analoge des menschlichen interferon-alpha mit niedriger toxizität

Country Status (13)

Country Link
US (1) US6204022B1 (de)
EP (1) EP1025124B1 (de)
JP (2) JP2001520238A (de)
KR (2) KR100861007B1 (de)
CN (1) CN1240717C (de)
AT (1) ATE402957T1 (de)
AU (1) AU744774B2 (de)
CA (1) CA2308116C (de)
DE (1) DE69839812D1 (de)
DK (1) DK1025124T3 (de)
ES (1) ES2310931T3 (de)
TW (1) TW593336B (de)
WO (1) WO1999020653A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
EP1212364A1 (de) * 1999-08-27 2002-06-12 University Of Florida STOFFE UND VERFAHREN ZUR HEMMUNG DER IgE PRODUKTION
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2003016472A2 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
AU2002365436B8 (en) * 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2518150C (en) * 2003-03-03 2015-08-11 Board Of Regents, The University Of Texas System Methods and compositions involving mda-7
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
AU2005211385B2 (en) * 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2597329C (en) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
EP1901777A2 (de) * 2005-06-20 2008-03-26 Pepgen Corporation Lang zirkulierende chimären mit niedriger toxizität von humanen interferon-alpha-analoga und interferon tau
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440251A4 (de) 2009-06-09 2013-01-16 Defyrus Inc Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (de) 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (de) 1986-03-31 1989-02-01 Interferon Sciences, Inc. Alpha-Interferon-Analogon
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Also Published As

Publication number Publication date
ES2310931T3 (es) 2009-01-16
US6204022B1 (en) 2001-03-20
CA2308116C (en) 2010-12-14
TW593336B (en) 2004-06-21
DK1025124T3 (da) 2008-10-06
EP1025124A1 (de) 2000-08-09
CA2308116A1 (en) 1999-04-29
EP1025124B1 (de) 2008-07-30
JP2001520238A (ja) 2001-10-30
AU744774B2 (en) 2002-03-07
WO1999020653A1 (en) 1999-04-29
CN1276797A (zh) 2000-12-13
KR100861007B1 (ko) 2008-09-30
AU9807298A (en) 1999-05-10
CN1240717C (zh) 2006-02-08
KR20060015701A (ko) 2006-02-17
JP2008247926A (ja) 2008-10-16
ATE402957T1 (de) 2008-08-15
KR100586625B1 (ko) 2006-06-07
KR20010031206A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ATE388963T1 (de) Homogene herstellungen von il-29
EE05111B1 (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
NO952744D0 (no) Cytokinbegrensende midler
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
DE59810596D1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
ZA896980B (en) Peptide compounds
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
DE59108947D1 (de) Neues menschliches, rekombinantes interferon gamma
DE69106407T2 (de) Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal.
AU2003274173A1 (en) Peptides and recombinant proteins mimicking interferons
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
MX9702475A (es) Analogos del factor de crecimiento acido de fibroblasto que tienen estabilidad y acticidad biologica mejoradas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition